GLOW is a name used for a blend of GHK-Cu, BPC-157 and TB-500. It is promoted for skin quality and recovery, but research on those ingredients does not establish that the combined blend delivers those benefits in people. The most useful starting point is the actual label: what is in the vial, how much of each ingredient it contains, and whether the research tested that same product.
The GLOW 70 mg formulation referenced here contains 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. Pure Lab Peptides lists it for laboratory research only. This identifies the product; it is not evidence of clinical effectiveness. [1]
Related reference: The GLOW 70 mg vial page contains the product-specific concentration and measurement chart. A calculation is separate from evidence that a treatment is appropriate.
What is in the GLOW peptide blend?
| Component | Amount in the vial | Research context |
|---|---|---|
| GHK-Cu | 50 mg | Copper-peptide research in skin cells and selected topical formulations. [2] |
| BPC-157 | 10 mg | Animal tissue-healing research and limited early human reports. [3][4] |
| TB-500 | 10 mg | The name requires careful identity checking; fragment research is not interchangeable with full-length thymosin beta-4. [5] |
That is 70 mg in total, not 70 mg of each ingredient. The name “GLOW” doesn’t define a universal pharmaceutical specification, so check the ratio on each product’s label.
Does GLOW improve skin, collagen or wrinkles?
The skin rationale comes mainly from GHK-Cu. A 2016 study investigated collagen and elastin production in cultured human skin cells and tested a topical, nano-carrier GHK-Cu formulation in 40 women over eight weeks. The topical formulation improved measured wrinkle parameters relative to comparison products. [2]
That is a specific and interesting finding. It is not a trial of injected GLOW. The route, formulation and other ingredients are different. Even the topical study does not establish that every copper-peptide serum will perform identically.
Claims about brighter skin, tighter skin, stronger hair and faster whole-body recovery are often grouped together. They need different measurements and different studies. This evidence does not establish hair regrowth, systemic anti-aging or a predictable cosmetic result from the three-component blend. For more detail on the ingredient itself, see our GHK-Cu research guide.
What about injury recovery and tissue repair?
BPC-157 has animal research relevant to this question. In a rat Achilles-tendon injury study, investigators reported improved healing measures. A surgically injured rat tendon, however, is not the same as a chronic sports injury in a person. [3]
The small human BPC-157 literature also needs proportion. A 2025 intravenous safety pilot included only two people, both with prior exposure. It reported no adverse effects during the brief observation period. It did not test GLOW, compare injury recovery with placebo or establish long-term safety. [4]
TB-500 introduces another complication. Pure Lab Peptides identifies this blend’s component as full-length, 43-amino-acid thymosin beta-4. A 2012 analytical study instead identified an acetylated seven-amino-acid fragment in a different TB-500 preparation. That study does not characterize this product. A supplier’s identity documentation matters more than the shorthand name. [1][5]
Do the ingredients work better together?
That has not been established by the studies cited here. A combination needs its own evaluation of benefit, dose relationship, stability and safety. Three plausible mechanisms do not automatically add up to a proven result.
“Synergy” has a specific meaning: the combined effect exceeds what would be expected from the components. Demonstrating that requires an appropriate comparison, not just a description of three pathways. The same applies to claims that one ingredient offsets another ingredient’s risks.
Side effects and safety questions
Reliable side-effect rates for the finished GLOW blend are not established by these studies. FDA has described potential immune-reaction and impurity concerns for BPC-157 and injectable GHK-Cu, together with limited safety information. Its separate assessment of thymosin beta-4 fragment should not be confused with evaluation of this blend’s stated full-length component. [6]
A topical product’s tolerability cannot settle the safety of an injectable blend. Nor does a purity percentage answer every question about identity, sterility, contaminants or how a person will respond.
Anyone considering a peptide product should review their medicines and medical history with a qualified clinician. An online checklist cannot establish safety during pregnancy, breastfeeding, cancer treatment or complex illness. New symptoms after an injection should not be dismissed as a necessary stage of “healing.”
How long does GLOW take to work?
There is no reliable blend-specific timeline in the evidence reviewed here. The eight-week topical GHK-Cu study does not establish when an injectable GLOW product would produce a visible change. [2]
Before-and-after photos are especially hard to interpret when lighting, skin care, training, sleep or other treatments change at the same time. A consistent photograph may document a change, but it does not prove which intervention caused it.
Common questions about GLOW
Is GLOW the same thing as GHK-Cu?
No. GHK-Cu is one component of the blend described here. “Glow peptide” is sometimes used loosely for copper-peptide skin products, so check the ingredient list rather than relying on the name.
Can GLOW be combined with NAD+?
The cited studies do not establish the safety or benefit of that combination. Adding another product also makes it harder to attribute a reaction or improvement. Discuss combinations with a clinician rather than assuming separate ingredients have been tested together.
Is there a standard GLOW dosage or cycle?
The ingredient studies do not establish a universal regimen for this blend. Vial contents, concentration and syringe volume are different quantities. An accurate calculation does not validate a cycle or make it a clinical recommendation.
Does compounding mean the blend is FDA-approved?
No. FDA explains that compounded drugs are not FDA-approved and do not undergo the same premarket verification of safety, effectiveness and quality. A compounding status discussion should not be presented as approval of a finished GLOW product. [7]
Bottom line: GLOW brings together three research ingredients, but the combination is the unanswered question. Keep ingredient findings, product composition and demonstrated human outcomes separate when evaluating its claims.
References
- Pure Lab Peptides. GLOW 70 mg blend product listing. Product composition and research-use designation only.
- Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science. 2016.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003.
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. 2025.
- Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma. Journal of Chromatography A. 2012.
- FDA. Certain bulk drug substances that may present significant safety risks.
- FDA. Compounding and the FDA: questions and answers.